Αποτελέσματα Αναζήτησης
Systemic lupus erythematous (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens. Due to the heterogeneous nature of lupus, it has been challenging to identify markers that are sensitive and specific enough for its diagnosis and monitoring.
- Combining DNA-microarray Data in Systemic Lupus Erythematosus
Application of DNA-microarray meta-analysis methods to SLE....
- Combining DNA-microarray Data in Systemic Lupus Erythematosus
4 Αυγ 2023 · Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multisystemic involvement. The condition has several phenotypes, with varying clinical presentations from mild mucocutaneous manifestations to multiorgan and severe central nervous system involvement.
16 Ιουν 2023 · Clinical manifestations – Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a wide range of clinical and serologic manifestations that can affect virtually any organ. The disease course is often marked by remissions and relapses and may vary from mild to severe.
Systemic lupus erythematosus (SLE) is a multisystem chronic autoimmune disease with a relapsing and remitting course. Its prevalence is higher in women of childbearing age, with a female predominance of 9:1 . The exact etiology of this disease is not understood well.
17 Απρ 2024 · Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterised by the presence of autoantibodies towards nuclear antigens, immune complex deposition, and chronic inflammation at classic target organs such as skin, joints, and kidneys.
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease of variable severity and course, characterised by a tendency for flare (figure 1).1 In SLE, both innate and adaptive immune responses are involved.
5 Οκτ 2023 · Systemic lupus erythematosus (SLE) is a generalised disorder that can affect any system. Symptoms and signs may accumulate over time. The diagnosis is made using 2019 criteria recommended by the American College of Rheumatology and the European League Against Rheumatology. Treatments for mild to moderate serositis or arthritis include ...
